Book contents
- Anemia
- Anemia
- Copyright page
- Contents
- Contributors
- Preface
- Section 1 The Normal Human Red Blood Cell
- Section 2 The Patient with Anemia
- Section 3 Specific Forms of Anemia
- Section 3, Part A Microcytic Anemias
- Section 3, Part B Macrocytic Anemias
- Section 3, Part C Hemoglobinopathies
- Section 3, Part D Hemolytic Anemias
- Section 3, Part E Hypoplastic Anemias
- Section 4 Secondary Anemias
- Section 5 Management of Anemia
- Section 6 Summary
- Index
- References
Section 3, Part A - Microcytic Anemias
from Section 3 - Specific Forms of Anemia
Published online by Cambridge University Press: 18 April 2018
Book contents
- Anemia
- Anemia
- Copyright page
- Contents
- Contributors
- Preface
- Section 1 The Normal Human Red Blood Cell
- Section 2 The Patient with Anemia
- Section 3 Specific Forms of Anemia
- Section 3, Part A Microcytic Anemias
- Section 3, Part B Macrocytic Anemias
- Section 3, Part C Hemoglobinopathies
- Section 3, Part D Hemolytic Anemias
- Section 3, Part E Hypoplastic Anemias
- Section 4 Secondary Anemias
- Section 5 Management of Anemia
- Section 6 Summary
- Index
- References
- Type
- Chapter
- Information
- AnemiaPathophysiology, Diagnosis, and Management, pp. 39 - 58Publisher: Cambridge University PressPrint publication year: 2017
References
References
Black, RE, Allen, LH, Bhutta, ZA, Caulfield, LE, de Onis, M, Ezzati, M, Mathers, C, et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet. 2008; 371:243–260.Google Scholar
Ganz, T, Nemeth, E. Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med. 2012; 2:a011668.Google Scholar
Ganz, T, Nemeth, E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823:1434–1443.Google Scholar
Miller, JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013; 3.CrossRefGoogle ScholarPubMed
Andrews, NC. Forging a field: the golden age of iron biology. Blood. 2008; 112:219–230.Google Scholar
Hentze, MW, Muckenthaler, MU, Andrews, NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117:285–297.Google Scholar
Pigeon, C, Ilyin, G, Courselaud, B, Leroyer, P, Turlin, B, Brissot, P, Loreal, O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001; 276:7811–7819.Google Scholar
Bolondi, G, Garuti, C, Corradini, E, Zoller, H, Vogel, W, Finkenstedt, A, Babitt, JL, et al. Altered hepatic BMP signaling pathway in human HFE hemochromatosis. Blood Cells Mol Dis. 2010; 45:308–312.CrossRefGoogle ScholarPubMed
Kemna, E, Pickkers, P, Nemeth, E, van der Hoeven, H, Swinkels, D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005; 106:1864–1866.Google Scholar
Nemeth, E, Rivera, S, Gabayan, V, Keller, C, Taudorf, S, Pedersen, BK, Ganz, T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113:1271–1276.Google Scholar
Nicolas, G, Chauvet, C, Viatte, L, Danan, JL, Bigard, X, Devaux, I, Beaumont, C, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110:1037–1044.Google Scholar
Andriopoulos, B Jr., Corradini, E, Xia, Y, Faasse, SA, Chen, S, Grgurevic, L, Knutson, MD, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41:482–487.Google Scholar
Verga Falzacappa, MV, Casanovas, G, Hentze, MW, Muckenthaler, MU. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med (Berl). 2008; 86:531–540.Google Scholar
Zhang, AS, Anderson, SA, Meyers, KR, Hernandez, C, Eisenstein, RS, Enns, CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem. 2007; 282:12547–12556.CrossRefGoogle ScholarPubMed
Lin, L, Nemeth, E, Goodnough, JB, Thapa, DR, Gabayan, V, Ganz, T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis. 2008; 40:122–131.Google Scholar
Silvestri, L, Pagani, A, Camaschella, C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008; 111:924–931.Google Scholar
Silvestri, L, Pagani, A, Nai, A, De Domenico, I, Kaplan, J, Camaschella, C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008; 8:502–511.Google Scholar
Lin, L, Goldberg, YP, Ganz, T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005; 106:2884–2889.Google Scholar
Babitt, JL, Huang, FW, Xia, Y, Sidis, Y, Andrews, NC, Lin, HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007; 117:1933–1939.CrossRefGoogle ScholarPubMed
Du, X, She, E, Gelbart, T, Truksa, J, Lee, P, Xia, Y, Khovananth, K, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008; 320:1088–1092.Google Scholar
Nemeth, E, Tuttle, MS, Powelson, J, Vaughn, MB, Donovan, A, Ward, DM, Ganz, T, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306:2090–2093.Google Scholar
Fraenkel, PG, Traver, D, Donovan, A, Zahrieh, D, Zon, LI. Ferroportin1 is required for normal iron cycling in zebrafish. J Clin Invest. 2005; 115:1532–1541.Google Scholar
James, AH, Kouides, PA, Abdul-Kadir, R, Dietrich, JE, Edlund, M, Federici, AB, Halimeh, S, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011; 158:124–134.Google Scholar
Khalafallah, AA, Dennis, AE. Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. J Pregnancy. 2012; 2012:630519.Google Scholar
Christensen, L, Sguassero, Y, Cuesta, CB. Anemia and compliance to oral iron supplementation in a sample of children attending the public health network of Rosario, Santa Fe. Arch Argent Pediatr. 2013; 111:288–294.Google Scholar
Bregman, DB, Morris, D, Koch, TA, He, A, Goodnough, LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013; 88:97–101.Google Scholar
Auerbach, M, Ballard, H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010; 2010:338–347.Google Scholar
Khalafallah, AA, Dennis, AE, Ogden, K, Robertson, I, Charlton, RH, Bellette, JM, Shady, JL, et al. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open. 2012; 2.Google Scholar
Vaziri, ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis. 2013; 61:992–1000.Google Scholar
References
Bottomley, SS, Fleming, MD. Sideroblastic anemia: diagnosis and management. Hematology/Oncology Clinics of North America. 2014; 28(4):653–670. Epub 2014/07/30.Google Scholar
Mufti, GJ, Bennett, JM, Goasguen, J, Bain, BJ, Baumann, I, Brunning, R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008; 93(11):1712–1717. Epub 2008/10/08.Google Scholar
Alcindor, T, Bridges, KR. Sideroblastic anaemias. British Journal of Haematology. 2002; 116(4):733–743.Google Scholar
McLintock, LA, Fitzsimons, EJ. Erythroblast iron metabolism in sideroblastic and sideropenic states. Hematology. 2002; 7(3):189–195. Epub 2002/09/24.Google Scholar
Bottomley, SS, Healy, HM, Brandenburg, MA, May, BK. 5-Aminolevulinate synthase in sideroblastic anemias: mRNA and enzyme activity levels in bone marrow cells. American Journal of Hematology. 1992; 41(2):76–83.Google Scholar
Cazzola, M, Invernizzi, R, Bergamaschi, G, Levi, S, Corsi, B, Travaglino, E, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 2003; 101(5):1996–2000. Epub 2002/10/31.Google Scholar
Rovo, A, Stussi, G, Meyer-Monard, S, Favre, G, Tsakiris, D, Heim, D, et al. Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood. International Journal of Laboratory Hematology. 2010; 32(3):329–335. Epub 2009/08/27.Google Scholar
Takagi, S, Tanaka, O, Origasa, H, Miura, Y. Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1999; 17(1):277–283. Epub 1999/08/24.Google Scholar
Zarco, MA, Feliu, E, Rozman, C, Masat, T, Aymerich, M, Jou, JM, et al. Ultrastructural study of erythrocytes containing Pappenheimer bodies in a case of congenital sideroblastic anaemia (CSA). British Journal of Haematology. 1991; 78(4):577–578. Epub 1991/08/01.Google Scholar
Broseus, J, Alpermann, T, Wulfert, M, Florensa Brichs, L, Jeromin, S, Lippert, E, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013; 27(9):1826–1831. Epub 2013/04/19.CrossRefGoogle ScholarPubMed
Parry, GJ, Bredesen, DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985; 35(10):1466–1468. Epub 1985/10/01.Google Scholar
Malcovati, L. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. Clinical Lymphoma & Myeloma. 2009; 9 Suppl 3:S305–311. Epub 2009/09/26.Google Scholar
Broliden, PA, Dahl, IM, Hast, R, Johansson, B, Juvonen, E, Kjeldsen, L, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006; 91(5):667–770. Epub 2006/05/04.Google Scholar
Takeuchi, M, Tada, A, Yoshimoto, S, Takahashi, K. Anemia and neutropenia due to copper deficiency during long-term total parenteral nutrition. [Rinsho ketsueki] The Japanese Journal of Clinical Hematology. 1993; 34(2):171–176. Epub 1993/02/01.Google Scholar
Iwase, O, Iwama, H, Okabe, S, Ando, K, Yaguchi, M, Miyazawa, K, et al. Refractory anemia with ringed sideroblasts with a low IPSS score progressed rapidly with de novo appearance of multiple karyotypic abnormalities and into acute erythroleukemia (AML-M6A). Leukemia Research. 2000; 24(7):597–600. Epub 2000/06/27.Google Scholar
Bernasconi, P, Alessandrino, EP, Boni, M, Bonfichi, M, Morra, E, Lazzarino, M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. American Journal of Hematology. 1994; 46(4):270–277. Epub 1994/08/01.CrossRefGoogle ScholarPubMed
References
Weatherall, DJ, Clegg, JB. The Thalassaemia Syndromes, 4th ed. Oxford, Blackwell Science; 2001.CrossRefGoogle Scholar
Weatherall, DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci. 2010; 1202:17–23.Google Scholar
Patrinos, GP, Giardine, B, Riemer, C, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucl Acids Res. 2004;32:D537–541. http://globin.cse.psu.edu/hbvar/menu.htmlGoogle Scholar
Thein, SL. The molecular basis of β-thalassemia. In: Weatherall, DJ, Schechter, AN, Nathan, DG, eds. Hemoglobin and Its Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013:159–182.Google Scholar
Verhovsek, MM, Shah, NR, Wilcox, I, et al. Severe fetal and neonatal hemolytic anemia due to a 198 kb deletion removing the complete β-globin gene cluster. Pediatr Blood Cancer. 2012; 59:941–944.CrossRefGoogle ScholarPubMed
Krishnamurti, L, Chui, DHK, Dallaire, M, et al. Co-inheritance of α-thalassemia-1 and hemoglobin E/β[0]-thalassemia: important implications for neonatal screening and genetic counseling. J Pediatr. 1998; 132:863–865.Google Scholar
Luo, H-Y, Chui, DHK. Diverse haematological phenotypes of β-thalassemia carriers. Ann N Y Acad Sci. 2016; 1368:49–55.Google Scholar
Cunningham, MJ, Macklin, EA, Neufeld, EJ, et al. Complications of β-thalassemia major in North America. Blood. 2004; 104:34–39.Google Scholar
Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older—United States, 2013. MMWR. 2013; 62(Suppl 1).Google Scholar
Verhovsek, M, McFarlane, A. Abnormalities in red blood cells. In: McKean, S, ed. Principles and Practice of Hospital Medicine, 1st ed. McGraw-Hill Professional; 2012.Google Scholar
Sabloff, M, Chandy, M, Wang, Z, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011; 117:1745–1750.Google Scholar
Locatelli, F, Kabbara, N, Ruggeri, A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013; 122:1072–1078.Google Scholar
Musallam, KM, Taher, AT, Cappellini, MD, et al. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013; 121:2199–2212.Google Scholar
Canver, MC, Orkin, SH. Customizing the genome as therapy for the β-hemoglobinopathies. Blood. 2016; 127:2536–2545.Google Scholar
Thompson, AA, Kwiatkowski, J, Rasko, J, et al. Lentiglobin gene therapy for transfusion-dependent β-thalassemia: update from the Northstar Hgb-204 phase 1/2 clinical study. Blood. 2016; 128:Abstract 1175.Google Scholar
Thompson, AA, Kim, HY, Singer, ST, et al. Pregnancy outcomes in women with thalassemia in North America and the UK. Am J Hematol. 2013; 88:771–773.Google Scholar
Cao, A, Kan, YW. The prevention of thalassemia. In: Weatherall, DJ, Schechter, AN, Nathan, DG, eds. Hemoglobin and Its Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013:285–299.Google Scholar
Taher, AT, Musallam, KM, Cappellini, MD, et al. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011; 152:512–523.Google Scholar
Fucharoen, S, Weatherall, DJ. The hemoglobin E thalassemias. In: Hemoglobin and Its Diseases. Weatherall, DJ, Schechter, AN, Nathan, DG, eds. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013:229–243.Google Scholar
Cavazzana-Calvo, M, Payen, E, Negre, O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassemia. Nature. 2010; 467:318–322.Google Scholar
Chui, DHK, Fucharoen, S, Chan, V. Hemoglobin H disease: not necessarily a benign disorder. Blood. 2003; 101:791–800.Google Scholar
Chen, FE, Ooi, C, Ha, SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med. 2000; 343:544–550.Google Scholar
Lal, A, Goldrich, ML, Haines, DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med. 2011; 364:710–718.Google Scholar
Tongsong, T, Srisupundit, K, Luewan, S. Outcomes of pregnancies affected by hemoglobin H disease. Int J Gynaecol Obstet. 2009; 104:206–208.Google Scholar
Lorey, F, Charoenkwan, P, Witkowska, HE, et al. Hb H hydrops foetalis syndrome: a case report and review of literature. Br J Haematol. 2001; 115:72–78.Google Scholar
Higgs, DR, Buckle, VJ, Gibbons, R, Steensma, D. Unusual types of α thalassemia. In: Disorders of Hemoglobin Genetics, Pathophysiology, and Clinical Management, 2nd ed. Steinberg, MH, Forget, BG, Higgs, DR, Weatherall, DJ, Eds. Cambridge: Cambridge University Press; 2009:296–320.Google Scholar
Steensma, DP, Gibbons, RJ, Higgs, DR. Acquired α-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005; 105:443–452.Google Scholar
Benz, EJ Jr., Wu, CC, Sohani, AR. Case records of the Massachusetts General Hospital. Case 25-2011. A 62-year-old woman with anemia and paraspinal masses. N Engl J Med. 2011; 365:648–658.Google Scholar
Chui, DHK, Waye, JS. Hydrops fetalis caused by α-thalassemia: an emerging health care problem. Blood. 1998; 91:2213–2222.Google Scholar
Lau, Y-L, Chan, L-C, Chan, Y-YA, et al. Prevalence and genotypes of α- and β-thalassemias in Hong Kong: implications for population screening. N Engl J Med. 1997; 336:1298–1301.Google Scholar
Peng, CT, Liu, SC, Peng, YC, et al. Distribution of thalassemias and associated hemoglobinopathies identified by prenatal diagnosis in Taiwan. Blood Cells Mol Dis. 2013; 51:138–141.Google Scholar
Songdej, D, Babbs, C, Higgs, DR, et al. An international registry of survivors with Hb Bart’s hydrops fetalis syndrome. Blood. 2017; 129:1251–1259.Google Scholar
Leung, KY, Cheong, KB, Lee, CP, et al. Ultrasonographic prediction of homozygous α[0]-thalassemia using placental thickness, fetal cardiothoracic ratio and middle cerebral artery Doppler: alone or in combination? Ultrasound Obstet Gynecol. 2010; 35:149–154.Google Scholar